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Abstract
Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant 
tumors and plays important roles in multiple aspects of cancer aggressiveness. Thus, targeting 
STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. 
Bisindolylmaleimide alkaloid (BMA) has been shown to have anti-cancer activities and was 
thought to suppress tumor cell growth by inhibiting protein kinase C. In this study, we show that a 
newly synthesized BMA analogue, BMA097, is effective in suppressing tumor cell and xenograft 
growth and in inducing spontaneous apoptosis. We also provide evidence that BMA097 binds 
directly to the SH2 domain of STAT3 and inhibits STAT3 phosphorylation and activation, leading 
to reduced expression of STAT3 downstream target genes. Structure activity relationship analysis 
revealed that the hydroxymethyl group in the 2,5-dihydropyrrole-2,5-dione prohibits STAT3-
inhibitory activity of BMA analogues. Together, we conclude that the synthetic BMA analogues 
may be developed as anticancer drugs by targeting and binding to the SH2 domain of STAT3 and 
inhibiting the STAT3 signaling pathway.
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Introduction
STAT3, signal transducers and activators of transcription 3, is a member of transcription 
factors in the Janus kinase (JAK)/STAT signaling pathway and can be activated by multiple 
stimuli 1. Activation of STAT3 involves phosphorylation of its conserved Tyr705, 
dimerization, and translocation into nucleus, where it binds to STAT3-specific DNA 
elements and induces transcription of downstream target genes including survivin, Bcl-xl, 
and VEGF 2. Constitutive activation of STAT3 has been detected in a number of human 
malignancies including breast and lung cancers 3–7. Activated STAT3 is essential for cancer 
cell survival and inhibiting STAT3 signaling pathway causes apoptosis 8. Over-expression of 
a constitutively-activated STAT3c molecule transformed human mammary epithelial cells 9 
and subcutaneously-injected cells expressing STAT3c formed xenograft tumors 10. 
Transgenic over-expression of STAT3c in alveolar type II (ATII) epithelial cells of mice led 
to lung inflammation and consequently spontaneous lung bronchoalveolar adenocarcinoma 
11
.
Bioactive compounds of microbial origin such as bisindolylmaleimide alkaloid (BMA) have 
been shown to display a wide spectrum of structural diversity with versatile biological 
activities including anti-inflammatory, antibacterial, antiparasitic, antifungal, and anti-tumor 
activities 12. For example, staurosporine, a structurally and biosynthesis-related natural 
product of BMA, has been shown to possess various strong biological activities such as anti-
proliferation possibly via inhibiting protein kinase C 13. However, it has also been shown 
that BMA induces apoptosis by inhibiting other pathways such as Wnt/β-catenin signaling 
in addition to inhibiting protein kinase C 14.
In this study, we tested a class of novel BMA derivatives, synthesized based on a 3,4-
diindolyl-2,5-dihydropyrrole-2,5-dione nucleus, for their potential activity in inhibiting 
STAT3 signaling pathway and inducing cancer cell apoptosis. We found that the synthetic 
BMA analogues are effective in suppressing tumor cell proliferation, inducing spontaneous 
apoptosis, and inhibiting xenograft tumor growth, possibly by binding directly to the SH2 
domain of STAT3 and inhibiting STAT3 phosphorylation and activation. Thus, synthetic 
BMA analogues may be developed as anticancer drugs by targeting STAT3 signaling 
pathway.
MATERIALS AND METHODS
Materials
MTT [3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide], DAPI [4′,6-diamidino-2-
phenylindole], and JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl 
benzimidazolocarbocyanine iodide) were purchased from Sigma (St. Louis, MO). All 
electrophoresis reagents and polyvinylidene difluoride (PVDF) membranes were purchased 
from Bio-Rad (Hercules, CA). The antibodies against pJAK2 (3776s), pSTAT3 (9145s, 
9134p), JAK2 (3230s), STAT3 (9139s), and cleaved caspase 3 (9661s) were obtained from 
Cell Signaling Technology (Danvers, MA). Antibodies against cyclin D1 (SC-753) and Bcl-
xL (SC-8392) were from Santa Cruze Biotechnology (Dallas, TX). DMEM and Ham’s F-12 
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were purchased from Media Tech. (Herndon, CA). All other chemicals were of molecular 
biology grade from Sigma or Fisher Scientific (Chicago, IL).
Cell lines and culture
Human breast cancer cell lines MCF-7, MDA-MB-231, and MDA-MB-468 were from 
ATCC and cultured in DMEM supplemented with 10% fetal bovine serum (Invitrogen, 
USA) in a humidified atmosphere with 5% CO2 at 37 °C. The noncancerous mammary 
epithelial cell line MCF10A cells, also from ATCC, were cultured in DMEM/F12 (50/50) 
with 10% equine serum, 10ug/mL insulin, 25 ng/mL EGF, 500 ng/mL hydrocortisone, and 
100 ng/mL cholera toxin. All media contained 100 μg/ml penicillin and 100 μg/ml 
streptomycin. All cell lines were authenticated by short tandem repeat analysis on January 
21, 2013 and then on August 3, 2016.
Synthesis and analysis of BMA analogues
BMA analogues were synthesized (Figure 1A) and their structures were unequivocally 
determined using NMR and MS as we previously described 15. To synthesize compound 1, 
2-(1H-indol-3-yl)acetic acid (3.5 g, 20 mmol) was added to a stirred suspension of NaH (4 
g, 100 mmol, mixture of 60% NaH in mineral oil) in THF (80 mL) at 0°C. The resulting 
mixture was stirred for 30 min followed by dropwise addition of ethyl iodide (5 mL, 60 
mmol) in THF (30 mL), allowed to warm to room temperature (RT), and stirred overnight. 
The reaction mixture was then cooled to 0°C and quenched by addition of 10 mL MeOH and 
20 mL H2O followed by extraction with Et2O (2 × 100 mL). The aqueous layer was 
acidified by addition of 6N hydrochloric acid (30 mL) and extracted with ethyl acetate 
(EtOAc, 2 × 100 mL). The combined organic extracts were washed with H2O (2 × 100 mL) 
and brine (2 × 100 mL), dried over anhydrous Na2SO4, filtered and concentrated under 
vacuum. The residue was purified by flash chromatography (1:3 EtOAc-petroleum ether, 
v/v) to yield 2-(1-ethyl-1H-indol-3-yl)acetic acid (compound 1) as a colorless solid (3.87 g, 
95% yield).
Using the same procedures, 2-[1-(3-cyanopropyl)-1H-indol-3-yl]acetic acid (5a) was 
synthesized as a colorless solid (541 mg, 30% yield) from 2-(1H-indol-3-yl)acetic acid (1.4 
g, 8 mmol), NaH (1.6 g, 40 mmol) and 4-bromobutanenitrile (2.4 mL, 24 mmol); 2-(1-(4-
cyanobutyl)-1H-indol-3-yl)acetic acid (6a) was synthesized as a colorless solid (1.69 g, 83% 
yield) from 2-(1H-indol-3-yl)acetic acid (1.4 g, 8 mmol), NaH (1.6 g, 40 mmol) and 5-
bromobutanenitrile (2 mL, 16 mmol).
To synthesize compound 2a, indole (702 mg, 6.0 mmol) was added to a stirred suspension of 
NaH (360 mg, 9.0 mmol, mixture of 60% NaH in mineral oil) in MeCN (80 mL) at −5°C. 
The resulting mixture was stirred for 30 min followed by dropwise addition of 3-
bromopropanenitrile (744 μL, 9.0 mmol), allowed to warm to RT and stirred for 24 hrs, 
followed by quenching with addition of saturated aqueous NH4Cl solution (100 mL) and 
extraction with EtOAc (2 × 100 mL). The combined organic layers were washed with H2O 
(2 × 100 mL) and brine (2 × 100 mL), dried over anhydrous Na2SO4, filtered and 
concentrated under vacuum. The residue was purified by flash chromatography (1:15 
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EtOAc-petroleum ether, v/v) to give 3-(1H-indol-1-yl)propanenitrile (2a) as a colorless oil 
(949 mg, 94% yield).
Using the same procedures, 4-(1H-indol-1-yl)butanenitrile (3a) was synthesized as a 
colorless oil (1.04 g, 57% yield) from indole (1.17 g, 10 mmol), NaH (0.6 g, 15 mmol) and 
4-bromobutanenitrile (1.6 mL, 15 mmol), and purified by flash chromatography (1:20 
EtOAc-petroleum ether, v/v); 5-(1H-indol-1-yl)pentanenitrile (4a) was synthesized as a 
colorless oil (0.63 g, 83% yield) from indole (0.59 g, 5 mmol), NaH (0.30 g, 7.5 mmol) and 
5-bromopentanenitrile (880 μL, 7.5 mmol) and purified by flash chromatography (1:10 
EtOAc-petroleum ether, v/v); 1-benzyl-1H-indole (7a) was synthesized as a colorless solid 
(1.0 g, 99% yield) from indole (585 mg, 5 mmol), NaH (300 mg, 7.5 mmol), and benzyl 
bromide (0.89 mL, 7.5 mmol) in DMF (30 mL), and purified by flash chromatography 
(1:100 EtOAc-petroleum ether, v/v).
To synthesize compound 2b, oxalyl chloride (1.11 g, 8.72 mmol) was added to a solution of 
2a (988 mg, 5.81 mmol) in CH2Cl2 (25 mL) at −5°C. The resulting mixture was stirred for 4 
hrs and allowed to warm to RT and then concentrated under vacuum and redissolved in 30 
mL CH2Cl2. The resulting solution was added to a mixture of compound 1 (1.18 g, 5.81 
mmol) and triethylamine (Et3N, 1.18 g, 11.64 mmol) in CH2Cl2 (30 mL) and stirred 
overnight followed by removing the solvent under vacuum. The residue was purified by 
flash chromatography (1:2 EtOAc-petroleum ether, v/v), leading to 2-(1-ethyl-1H-indol-3-
yl)-3-[1-(2-cyanoethyl)-1H-indol-3-yl]maleic anhydride (2b) as a red powder (530 mg, 23% 
yield).
Using the same procedures, 2-(1-ethyl-1H-indol-3-yl)-3-[1-(3-cyanopropyl)-1H-indol-3-
yl]maleic anhydride (3b) was prepared as a red powder (415 mg, 45% yield) from 3a (407 
mg, 2.21 mmol), oxalyl chloride (421 mg, 3.32 mmol), 1 (449 mg, 2.21 mmol) and Et3N 
(447 mg, 4.42 mmol), and purified by flash chromatography (1:3 EtOAc-petroleum ether, 
v/v); 2-(1-ethyl-1H-indol-3-yl)-3-[1-(4-cyanobutyl)-1H-indol-3-yl]maleic anhydride (4b) 
was synthesized as a red powder (712 mg, 51% yield) from 4a (627 mg, 3.17 mmol), oxalyl 
chloride (604 mg, 4.76 mmol), 1 (644 mg, 3.17 mmol) and Et3N (640 mg, 6.34 mmol); 2,3-
bis[1-(3-cyanopropyl)-1H-indol-3-yl]maleic anhydride (5b) was synthesized as a red powder 
(500 mg, 44% yield) from 3a (452 mg, 2.46 mmol), oxalyl chloride (469 mg, 3.69 mmol), 
5a (595 mg, 2.46 mmol) and Et3N (497 mg, 4.92 mmol), and purified by flash 
chromatography (1:1 EtOAc-petroleum ether, v/v); 2,3-bis[1-(4-cyanobutyl)-1H-indol-3-yl] 
maleic anhydride (6b) was synthesized as a red powder (900 mg, 32% yield) from 4a (1140 
mg, 5.76 mmol), oxalyl chloride (1097 mg, 8.64 mmol), 6a (1470 mg, 5.76 mmol) and Et3N 
(1163 mg, 11.5 mmol); 2-(1-ethyl-1H-indol-3-yl)-3-(1-benzyl-1H-indol-3-yl)maleic 
anhydride (7b) was synthesized as a red powder (300 mg, 39% yield) from 7a (356 mg, 1.72 
mmol), 1 (0.397 g, 1.92 mmol), oxalyl chloride (0.25 ml, 2.88 mmol) and Et3N (0.531 mL, 
3.84 mmol), and purified by flash chromatography (1:5 EtOAc-petroleum ether, v/v).
BMA016 was synthesized by first mixing 2b (230 mg, 0.56 mmol) in DMF (10 mL) with 
the mixture of HMDS (12 mL, 57 mmol) and MeOH (1.2 mL, 28.5 mmol) in DMF (5 mL), 
which was sealed and stirred at RT overnight followed by quenching the reaction with 
addition of ice-cold water (25 mL), extraction with EtOAc (2 × 100 mL), and washing with 
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H2O (3 × 100 mL). The organic layers were combined and dried over anhydrous Na2SO4, 
filtered and evaporated under vacuum. The residue was purified by flash chromatography 
(4:1 CH2Cl2-petroleum ether, v/v) to give 2-(1-ethyl-1H-indol-3-yl)-3-[1-(2-
cyanoethyl)-1H-indol-3-yl]maleimide (BMA016) as a red powder (219 mg, 95% yield).
Using the same procedures, 2-(1-ethyl-1H-indol-3-yl)-3-[1-(3-cyanopropyl)-1H-indol-3-
yl]maleimide (BMA019) was synthesized as a red powder (203 mg, 98% yield) from 3b 
(205 mg, 0.49 mmol), HMDS (10.2 mL, 48.5 mmol) and MeOH (0.97 mL, 24.3 mmol), and 
purified by flash chromatography (1:1 EtOAc-petroleum ether, v/v); 2-(1-ethyl-1H-indol-3-
yl)-3-[1-(4-cyanobutyl)-1H-indol-3-yl]maleimide (4c) was synthesized as a red powder (585 
mg, 95% yield) from 4b (616 mg, 1.14 mmol), HMDS (12 mL, 57 mmol) and MeOH (1.14 
mL, 28.5 mmol), and purified by flash chromatography (1:2 EtOAc-petroleum ether, v/v); 
2,3-bis[1-(3-cyanopropyl)-1H-indol-3-yl]maleimide (BMA097) was synthesized as a red 
powder (341 mg, 91% yield) from 5b (375 mg, 0.81 mmol), HMDS (375 mg, 0.81 mmol) 
and MeOH (0.66 mL, 16.2 mmol), and purified by flash chromatography (1:2 EtOAc-
petroleum ether, v/v); 2,3-bis[1-(4-cyanobutyl)-1H-indol-3-yl] maleimide (BMA100) was 
synthesized as red powder (426 mg, 90% yield) from 6b (470 mg, 0.96 mmol), HMDS (8.1 
mL, 38.4 mmol) and MeOH (0.77 mL, 19.2 mmol), and purified by flash chromatography 
(3:2 EtOAc-petroleum ether, v/v); 2-(1-ethyl-1H-indol-3-yl)-3-(1-benzyl-1H-indol-3-
yl)maleimide (7c) was synthesized as a red powder (426 mg, 90% yield) from 7b (260 mg, 
0.58 mmol), HMDS (2.44 mL, 11.7 mmol) and MeOH (0.23 mL, 5.8 mmol), and purified by 
flash chromatography (4:1 CH2Cl2-petroleum ether, v/v).
To synthesize BMA088, a suspension of 4c (6.7 mg, 14.4 μmol) and NaHCO3 (2.4 mg, 28.8 
μmol) in 37% HCHO (5 mL) was stirred for 10 hrs at 85°C. The reaction was stopped by 
addition of excess ice-cold water and extracted with EtOAc (2 × 50 mL) and washed twice 
with brine (2 × 50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrate under vacuum. The residue was purified by flash chromatography (1:4 EtOAc-
petroleum ether, v/v) to yield N-hydroxymethyl-2-(1-ethyl-1H-indol-3-yl)-3-[1-(4-
cyanobutyl)-1H-indol-3-yl] maleimide (BMA088) as a red powder (6.9 mg, 96% yield). N-
hydroxy-2-(1-ethyl-1H-indol-3-yl)-3-(1-hydroxy-1H-indol-3-yl)maleimide (BMA127) was 
prepared in a similar manner as a red powder (111 mg, 95% yield) from 7d (100 mg, 0.28 
mmol), NaHCO3 (71 mg, 0.84 mmol) and 37% HCHO (5 mL), and purified by flash 
chromatography (2:1 EtOAc-petroleum ether, v/v).
To synthesize 7d, 1M t-BuOK/THF (8.4 mL, 8.4 mmol) solution was mixed with a solution 
of 7c (100 mg, 0.225 mmol) in DMSO (0.85 mL, 12.0 mmol) and pure O2 was bubbled into 
the mixture for 30 minutes. The reaction was quenched by addition of saturated aqueous 
NH4Cl solution, extracted with EtOAc (2 × 100 mL), and washed with H2O (2 × 100 mL). 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under 
vacuum. The residue was purified by flash chromatography (6:1 CH2Cl2-ethyl acetate, v/v) 
to yield 2-(1-ethyl-1H-indol-3-yl)-3-(1H-indol-3-yl)maleimide (7d) as a red powder (70.5 
mg, 89% yield).
Analysis and characteristics of all compounds are described in the Supplemental Method.
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Docking and binding free energy estimation
The crystal structure of STAT3 was obtained from the RCSB protein data bank (ID: 1BG1) 
with missing residues modeled using ModLoop 16. Chain B was removed from the structure 
and only chain A was kept and prepared for docking by the UCSF Chimera Dock Prep 
module 17. Since Chain B was removed, the binding pocket in chain A for pTyr705 in chain 
B was chosen as the docking site. The 2D structure of BMA097 was converted to 3D format 
by ChemBioDraw 13.0, prepared using the UCSF Chimera Dock Prep module, and docked 
to the SH2 domain of STAT3 by DOCK6 suite 18. The binding free energies (ΔGbind) of 
BMA097 were calculated as we previously described 19. Briefly, 20-ns product MD 
simulations were performed and then 200 snapshots were extracted for enthalpy calculation 
using Generalized Born method and 20 frames were used to estimate entropy due to the 
expensiveness of the computation.
Luciferase reporter assay
MDA-MB-231-STAT3 cells (stably-transfected with STAT3-dependent luciferase reporter) 
were used for testing BMA as we previously described 20, 21. Briefly, the cells were treated 
with vehicle DMSO control or BMA compounds at different concentrations for various 
times followed by measurement of luciferase activity using a luciferase assay kit (Promega).
Western blot and real-time RT-PCR
Western blot and real-time RT-PCR analyses were performed as we previously described 
20, 21
. Briefly, following separation by SDS-PAGE and transfer onto PVDF membranes, the 
membranes were probed with primary antibodies and then HRP-conjugated secondary 
antibodies. The signals were detected using the Amersham™ ECL Western Blotting 
Detection Reagent (GE Healthcare, Uppsala, Sweden) and signal recorded using x-ray films.
The real time RT-PCR was performed using an ABI Prism@7500 Sequence Detection 
System (Applied Biosystems) with SYBR Green diction according to the manufacturer’s 
instruction as we previously described 20, 21. Primers used for PCR are 5′-
GGCCCCTCGTCATCAAGA-3′ (forward) and 5′-
TTTGACCAGCAACCTGACTTTAGT-3′ (reverse) for STAT3, 5′-
CTTCCTCTCCAAAATGCCAG-3′ (forward) and 5′-
AGAGATGGAAGGGGGAAAGA-3′ (reverse) for cyclin D1, 5′-
TGCATTGTTCCCATAGAGTTCCA-3′ (forward) and 5′-
CCTGAATGACCACCTAGAGCCTT-3′ (reverse) for Bcl-xL, and 5′-
AAGGACTCATGACCACAGTCCAT-3′ (forward) and 5′-
CCATCACGCCACAGTTTCC-3′ (reverse) for GAPDH. The threshold cycle (Ct) was 
defined as the PCR cycle number at which the reporter fluorescence crosses the threshold 
reflecting a statistically significant point above the calculated baseline. The relative level 
was calculated using 2ΔΔCt with GAPDH as an internal control.
Survival and apoptosis assays
The cytotoxicity of BMA097 was evaluated using MTT survival assay as previously 
described 20, 21. Briefly, 3–4×103 cells/well were seeded in 96-well plates and treated with 
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BMA097 at different concentrations for various times, followed by addition of MTT and 
analysis of viable cells.
The BD Pharmingen™ Annexin V-FITC Apoptosis Detection Kit was used to evaluate 
BMA097-induced apoptosis according to manufacturer’s instructions. Briefly, 3×105 cells/
well were seeded in 6-well plates and treated with BMA097 at different concentrations for 
various times followed by staining with annexin V-FITC and propidium iodide (PI) and 
FACS analysis using a flow cytometer (Becton Dickinson, USA). Both annexin V-
positive/PI negative and double-positive cells were considered apoptotic cells in this study.
Mitochondrial membrane potential Δψm depolarization was determined using a fluoresce 
probe JC-1 according to manufacturer’s instructions. Briefly, cells were exposed to 
BMA097 for 24 hours and stained with JC-1 (5 μg/mL) for 30 min at 37°C. Cells were then 
washed with PBS and intracellular fluorescence intensity of JC-1 was quantified using flow 
cytometry. Data analysis was performed using Cell Quest software (Becton Dickinson). The 
Δψm was calculated as the ratio of red (JC-1 aggregates) to green (JC-1 monomers) 
fluorescence.
Immunostaining
Immunofluorescence staining was performed as we previously described 22. Briefly, cells 
were seeded onto 12-mm round glass cover slips in 24-well plates and treated with or 
without BMA097 for 24 hours. Cells were washed and fixed in methanol/acetone (1:1) and 
permeabilized with 0.1% Triton X-100 before blocking with 3% BSA and staining with 
STAT3 or pSTAT3 antibody. The staining was detected using secondary antibody-conjugated 
with Alexa Fluor 555. Nuclei were counter-stained by DAPI before mounting the cover 
glasses onto slides for fluorescence imaging using a confocal microscope 23.
Pull-down assay
Pull-down assay using immobilized BMA097 was performed as previously described 20, 21. 
Briefly, BMA097 was incubated with CNBr-activated Sepharose 4B (CNBr-S4B) to 
immobilize BMA097. Sepharose-conjugated BMA097 was then blocked by 10% milk in the 
binding buffer (20 mmol/L Tris-HCl (pH 8.0), 150 mmol/L KCl, 1 mmol/L EDTA, 15% 
glycerol, 0.5% NP-40, 0.2 mmol/L PMSF and protease inhibitor cocktail) followed by 
mixing with cell lysate or purified STAT3 protein for pull-down assay. The pull-down 
materials were then subjected to separation on SDS-PAGE and Western blot analysis probed 
by STAT3 antibody or silver staining. For competition, cell lysate was pre-incubated with 
DMSO vehicle, 400 μM BMA097 or an irrelevant compound 20, 21 for 30 min at 37°C prior 
to pull down assay using immobilized BMA097. For elution, the pull-down materials were 
incubated in the presence of vehicle, 400 μM BMA097 or an irrelevant compound for 1 hour 
followed by centrifugation. The eluent supernatant was then collected for Western blot 
analysis.
In-vivo efficacy
For efficacy study, 1×107 MDA-MB-231 cells were first injected subcutaneously into the 
flank of a 5-week old Balb/c athymic (nu+/nu+) female mouse and allowed to proliferate for 
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two weeks. The exuberantly proliferating xenograft tumor mass was then collected and cut 
into ~1.5-mm thick pieces and inoculated subcutaneously on the left flank of 4–6 weeks old 
Balb/c athymic (nu+/nu+) female mice. When tumors reached ~100 mm3, the mice were 
randomized into four groups using an online tool (https://www.randomizer.org/) with 5 in 
each group and treated every 3 days for 18 days with vehicle only, 10 mg/kg or 40 mg/kg 
BMA097, and 0.6 mg/kg vincristine, respectively, via IP injection. The tumor volume and 
body weight were measured every 3 days. The treatments were not but measurements of 
tumor volume were blinded. Based on our preliminary experiments and experiences working 
with MDA-MB-231 cells as xenografts, 5 animals in each group were estimated that would 
give enough power without statistical analysis. All animals were included for final data 
analyses without any exclusion. The above in-vivo studies were approved by the Institutional 
Animal Care and Use Committee.
Statistical analysis
All experiments except in vivo studies were performed at least three times. Statistical 
analysis was performed with an analysis of variance (ANOVA) followed by the Turkey’s t-
test. P-values of <0.05 were considered statistically significant. For every figures, the 
statistical tests were appropriate and met the assumptions of the tests. However, the variance 
within and between each treatment group of the in-vivo study is different.
RESULTS
Synthesis of BMA derivatives
As shown in Figure 1A, 2-(1H-Indol-3-yl)acetic acid reacted with ethyl iodide and 
bromonitriles in the presence of sodium hydride (NaH) to yield compounds 1, 5a and 6a, 
respectively. Indole derivatives 2a–4a and 7a were synthesized by reaction of indole with 
bromonitriles and benzyl bromide, respectively, in the presence of NaH. Compounds 2a–4a 
and 7a reacted with oxalyl chloride, leading to acidylated intermediates that were used to 
react with compounds 1, 5a and 6a to afford bisindolylmaleic anhydrides 2b–7b. The 
anhydrides were subjected to aminolysis with hexamethyldisilazane (HMDS) and MeOH in 
DMF to produce the corresponding bisindolymaleimides BMA016, BMA019, 4c, BMA097, 
BMA100 and 7c. BMA088 was prepared from the nucleophilic addition of 4c with HCHO 
under basic condition. Compound 7c was subjected to deprotection of benzyl in the presence 
of t-BuOK, O2 and DMSO, followed by the additive reaction with HCHO and NaHCO3 to 
give BMA127 (Figure 1A).
Inhibition of STAT3 activity by BMA derivatives
To determine if BMA are potential STAT3 inhibitors, we tested 6 synthetic BMA derivatives 
for their effects on STAT3-dependent luciferase expression in a cell-based assay. As shown 
in Figure 1B, 5 BMA derivatives (BMA016, 019, 097, 100, and 127) significantly inhibited 
STAT3-dependent luciferase expression in MDA-MB-231 cells with BMA127 having the 
least inhibition and BMA088 having no inhibition.
The above findings also suggest that the hydroxymethyl group on the nitrogen in 2,5-
dihydropyrrole-2,5-dione in BMA088 and BMA127 may be inhibitory to BMA activity in 
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STAT3 inhibition. Furthermore, alteration in length or in end group of the two hydrocarbon 
chains on the indole may also affect the STAT3 inhibitory activity, although they do not 
appear to be very critical with possibly optimal length of the hydrocarbon chain in 
BMA097.
Because BMA097 appears to be most effective (Figure 1B), it was selected for further 
evaluation. Firstly, re-synthesized BMA097 was tested to verify its activity. Figure 2A–B 
show that the re-synthesized BMA097 inhibits STAT3-dependent luciferase expression in a 
dose- and time-dependent manner with an IC50 of ~1.8 μM and t1/2 of ~16 hrs. Furthermore, 
BMA097 inhibited the expression of STAT3 target genes, cyclin D1 and Bcl-xL, as 
determined using both real-time RT-PCR for mRNAs (Figure 2C) and by Western blot for 
proteins (Figure 3A), indicating that BMA097 inhibits the transcriptional activation of 
cyclin D1 and Bcl-xL gene possibly by inhibiting STAT3 activity.
BMA097 suppresses Tyr705 phosphorylation and activation of STAT3
To determine the mechanism of BMA097 inhibition of STAT3 activity, we first examined 
the phosphorylation status and activation of STAT3 following BMA097 treatment. Figure 
3A–B show that BMA097 inhibits phosphorylation of the Tyr705 in dose- and time-
dependent manners but not the phosphorylation of Ser727. It also had little effect on the level 
of total STAT3. Furthermore, BMA097 treatment reduced IL-6-induced phosphorylation and 
activation of STAT3 in serum-starved MDA-MB-231 cells (Figure 3C). Thus, BMA097 
likely inhibits STAT3 activity by inhibiting Tyr705 phosphorylation and activation of STAT3.
We next analyzed subcellular localization of STAT3 using both immunofluorescence 
staining and separation of nuclear and cytoplasmic fractions. As shown in Figure 3D–E, the 
nucleus-localized STAT3, representing the Tyr705-phosphorylated and activated STAT3, 
disappeared following BMA097 treatment, confirming that BMA097 inhibits Tyr705 
phosphorylation and activation and, thus, nuclear localization of STAT3.
It is well known that STAT3 activation following Tyr705 phosphorylation results in homo-
dimerization before relocalization into nucleus 24. To further determine if BMA097 
inhibition of Tyr705 phosphorylation would consequently reduce STAT3 dimerization and 
activation, we performed non-denaturing PAGE analysis of dimeric STAT3 following 
BMA097 treatment. As shown in Figure 3F–G, BMA097 inhibited STAT3 dimerization in 
dose- and time-dependent manners. Taken together, we conclude that BMA097 treatment 
likely inhibits STAT3 activation (phosphorylation and dimerization) and translocation into 
nucleus.
To determine if BMA097 inhibits STAT3 phosphorylation and activation possibly by 
inhibiting its upstream kinase JAK2, we performed Western blot analysis of JAK2 
Tyr1007/1008 phosphorylation and activation. Figure 3H shows that BMA097 treatment has 
no effect on the level of total JAK2 and does not inhibit JAK2 phosphorylation/activation. 
Thus, BMA097 inhibition of STAT3 phosphorylation and activation is unlikely by inhibiting 
its upstream kinase JAK2.
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BMA097 binds directly to STAT3 at the SH2 domain
Because BMA097 does not inhibit STAT3 upstream kinase JAK2, we hypothesized that 
BMA097 might bind directly to STAT3 at its SH2 domain and inhibit phosphorylation of 
Tyr705 and activation by JAK. To test this hypothesis, we first performed structural analysis 
of STAT3 (Pdb code: 1BG1) and docked BMA097 to the phospho-Tyr-binding pocket in the 
SH2 domain Next, we performed 20-ns molecular dynamics (MD) simulation on the docked 
STAT3-BMA097 complex and calculated the total binding free energies (ΔGbind) of 
BMA097. The difference of enthalpy (ΔHbind) is calculated to be −15.21 kcal/mol using 
Generalized Born method. The difference of entropy (ΔSbind) is estimated to be −10.71 
kcal/mol by normal mode analyses and its product with temperature (T). By solving the 
equation ΔGbind = ΔHbind − T ΔSbind, the total binding free energy is estimated to be −4.50 
kcal/mol, indicating a favorable binding of BMA097 to the SH2 domain of STAT3.
The frame with lowest total potential energy of the simulation was further examined. As 
shown in Figure 4A, BMA097 (pink) docked in the phospho-Try-binding pocket in the SH2 
domain (green). It appears that BMA097 interacts with the SH2 domain of STAT3 via 3 
strong hydrogen bonds (green lines in Figure 4B). Firstly, the nitrogen atom on the dioxo-
pyrrole ring of BMA097 interacts with the oxygen of Gln635 of STAT3 via a hydrogen bond. 
Secondly, the oxygen atom on the dioxo-pyrrole ring of BMA097 hydrogen bonds with the 
main chain nitrogen of Ser636 of STAT3. Finally, the nitrogen atom on the indole ring of 
BMA097 and the side chain oxygen of Ser636 of STAT3 forms the third hydrogen bond. In 
addition, residues Arg609, Glu612 and Glu638 interact with BMA097 via electrostatic 
interactions and residues Thr620, Val637 and Pro639 contribute to the binding of BMA097 via 
hydrophobic interactions.
To validate the above computational analysis and to determine if BMA097 binds directly to 
STAT3, we took advantage of the imino group of BMA097 and conjugated it to CNBr-
activated Sepharose for pull-down assay. As shown in Figure 4C, BMA097-conjugated 
Sepharose successfully pulled down STAT3 from lysate of MDA-MB-231 cells while 
control Sepharose and Sepharose-conjugated with an irrelevant compound did not. Pre-
treatment of cell lysate with excess BMA097 but not vehicle nor the irrelevant compound as 
competitors completely inhibited STAT3 pulldown by BMA097-conjugated Sepharose 
(Figure 4D). Furthermore, only excess BMA097 but not vehicle nor the irrelevant compound 
can elute STAT3 from BMA097-bound STAT3 (Figure 4E). These findings together suggest 
that STAT3 can bind to BMA097 via non-covalent interactions.
In above studies, total cell lysate was used and, thus, the interaction between STAT3 and 
BMA097 could be indirect via another protein. To rule out this possibility and to 
demonstrate that BMA097 binds directly to the SH2 domain of STAT3, we performed a 
pull-down assay using purified recombinant STAT3 followed by SDS-PAGE analysis with 
silver staining. Figure 4F shows the schematic domain structures of different recombinant 
STAT3 proteins for pull-down assays. Figure 4G shows that the recombinant STAT3 lacking 
the TAD domain (ΔTAD-C) can be successfully pulled down by immobilized BMA097. 
However, further deletion of the SH2 domain (ΔSH2-C) abolished the binding by BMA097, 
suggesting that the BMA097-binding site may be located in the SH2 domain of STAT3. To 
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confirm this finding, we engineered another construct for production of recombinant STAT3 
with only the carboxyl domains containing the SH2 domain. As shown in Figure 4G, this 
protein was successfully pulled down by immobilized BMA097. Together, these findings 
suggest that BMA097 may bind directly to STAT3 at its SH2 domain as predicted by 
docking analysis.
BMA097 inhibits survival and induces apoptosis of breast cancer cells
Previously it has been reported that STAT3 signaling is required for survival of breast cancer 
cells 25. Thus, we next tested if BMA097 suppresses survival of breast cancer cells and has 
any anticancer activity using MTT assay. As shown in Fig. 5A, BMA097 inhibited survival 
of breast cancer cell lines MDA-MB-231, MDA-MB-468, and MCF7 in dose- and time-
dependent manners. The IC50 for 48-hr treatments were estimated to be 3.6, 4.0, 6.4 μM for 
MDA-MB-231, MDA-MB-468, and MCF7 cells, respectively. These values at 72 hrs of 
treatments are reduced to 0.9, 1.8, and 3.9 μM, respectively. In contrast, the cytotoxicity of 
BMA097 is relatively low to non-cancerous human mammary epithelial cell line MCF10A 
with an IC50 of 10.6 at 48 hrs and 6.5 μM at 72 hrs of treatments (Supplemental Fig. S1). 
Thus, there may be a therapeutic window for BMA097.
Next, we examined the effect of BMA097 on apoptosis firstly using annexin V-FITC and PI 
staining and flow cytometry in MDA-MB-231 and MCF7 cells. Figure 5B shows that the 
proportion of cells stained with annexin V and PI increases following BMA097 treatment in 
a dose-dependent manner in both cell lines. The total annexin V-positive cells represent 
13.4%, 51.9% and 63.8% of the population for MDA-MB-231 and 7.8%, 34.2% and 48.1% 
for MCF-7 cells following treatment with 0, 2, and 4 μM BMA097 for 24 hrs, respectively. 
The population of annexin V-positive MDA-MB-231 cells also increases with time of 
treatment using 2 μM BMA097 (Figure 5C).
We also examined the effects of BMA097 treatment on mitochondrial membrane potential 
(Δψm) in both MDA-MB-231 and MCF-7 cells as another indicator of apoptosis. As shown 
in Figure 5D, BMA097 treatment induced Δψm loss in a dose-dependent manner for both 
cell lines. Together, the above findings suggest that BMA097 suppresses breast cancer cell 
survival likely by causing dose and time-dependent apoptosis.
BMA097 suppresses growth of xenograft tumors and STAT3 activation in vivo
We next evaluated the in-vivo anti-tumor activity of BMA097 in nude mice bearing MDA-
MB-231 xenografts. As shown in Figure 6A–C, the growth and final weight of MDA-
MB-231 xenograft tumors were effectively and significantly reduced by BMA097 treatment 
with doses at 10 and 40 mg/kg, similar to the vincristine control treatment group. Although 
the body weight of mice in all groups dropped slightly at the conclusion of the experiment 
(Figure 6A), possibly due to disease burden, there are no significant differences in body 
weight reduction between the control and treatment groups. Immuohistochemistry staining 
of the xenograft tumors shows that the tumors in the BMA097-treated group have reduced 
level of phosphorylated STAT3 compared to vehicle control treatment group (Figure 6D). 
BMA097 treatment also induced caspase 3 cleavage in the xenograft tumors (Figure 6D). 
These observations are consistent with our findings that BMA097 inhibits STAT3 
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phosphorylation and activation and induces apoptosis. Thus, BMA097 likely inhibits 
xenograft tumor growth by inhibiting STAT3 activation in vivo.
Discussion
Using rational screening of synthetic BMA analogues, we identified BMA097 as an 
effective inhibitor of STAT3 and a potential therapeutics for breast cancer treatment. It 
appears that BMA097 binds directly to the pTyr-binding pocket in the SH2 domain and, 
thus, effectively inhibits Tyr705 phosphorylation and activation by JAK2. The inhibition of 
STAT3 phosphorylation at Tyr705 and BMA097 occupation in the pTyr-binding pocket of the 
SH2 domain led to inhibition of STAT3 dimerization and translocation into nucleus for 
activation of its downstream target genes and, thus, inhibition of proliferation and induction 
of apoptosis. Thus, BMA097, as a synthetic derivative of BMA, may be developed as a 
potential therapeutics for breast cancer treatment by targeting STAT3.
Although BMA097 binds to and inhibits STAT3 activation, we cannot rule out the 
possibility that its effect on cancer cell survival and apoptosis may be compounded by its 
potential inhibition of PKC because bisindolylmaleimide are known to also inhibit PKC. 
However, BMA097 did not affect phosphorylation of Ser727 of STAT3, which is known to 
be phosphorylated by PKC 26. Thus, the specific synthetic analogue of bisindolymaleimide, 
BMA097, may not inhibit PKC. Indeed, it remains to be determined if BMA097 possibly 
inhibits other pathways such as Wnt/β-catenin signaling 14, which then contributes to 
BMA097-induced cell death.
Domain mapping of the binding site using purified recombinant STAT3 protein and pull-
down assay indicate that BMA097 likely binds directly to the SH2 domain as predicted 
using computational modeling. The predicted interaction between BMA097 and STAT3 also 
provides theoretical evidence that explains why attaching a hydroxymethyl group to the 
nitrogen in 2,5-dihydropyrrole-2,5-dione would result in reduction in activity. It is possible 
that the hydroxymethyl group forms an internal hydrogen bond with one of the oxygen in 
the dioxo-pyrrole ring and, thus, eliminates formation of two hydrogen bonding with STAT3, 
which would effectively reduce the binding of BMA088 and BMA127 to the SH2 domain of 
STAT3. However, exactly how and if BMA097 binds to the pocket in the SH2 domain of 
STAT3 requires further investigation using experimental approaches such as generating co-
crystal structures.
Although BMA097 has a potential therapeutic window with IC50 of 0.9–3.9 μM for breast 
cancer cells and 6.2 μM for non-cancerous mammary epithelial cells, developing it into 
cancer therapeutics by targeting STAT3 needs to be cautiously performed. STAT3 is known 
to play important roles in hematopoiesis and innate immunity 27, 28, chronic use of STAT3 
inhibitors may cause adverse effect on bone marrow and innate immunity. However, lack of 
weight loss and apparent phenotypic changes in the mouse model suggest that 40 mg/kg 
BMA097 in mice may not cause sever adverse effect and, thus, may warrant further 
development.
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Figure 1. Synthesis of BMA analogues and their effects on STAT3-dependent luciferase activity
(A) Synthesis of BMA analogues. a. NaH, CH3CH2I, THF: 1 95% yield; b. NaH, 
Br(CH2)nCN, MeCN: 2a 94% yield, 3a 57% yield, 4a 83% yield; c. (i) (COCl)2, CH2Cl2, 
(ii) (CH3CH2)3N, CH2Cl2: 2b 23% yield, 3b 45% yield, 4b 51% yield, 5b 44% yield, 6b 
32% yield, 7b 39% yield; d. HMDS, MeOH, DMF: BMA016 95% yield, BMA019 98% 
yield, 4c 95% yield, BMA097 91% yield, BMA100 90% yield, 7c 90% yield; e. 37% 
HCHO, NaHCO3, 85°C: BMA088 96% yield, : BMA127 95% yiled; f. NaH, Br(CH2)nCN, 
THF: 5a 30% yield, 6a 83% yiled; g. NaH, C6H5CH2Br, DMF: 7a 99% yiled; h. O2, 
DMSO, t-BuOK, THF: 7d 89% yiled. (B) Effect of BMA analogues on STAT3-dependent 
luciferase activity. Stable MDA-MB-231 cells expressing STAT3-dependent luciferase 
reporter were treated with synthetic BMA analogues or DMSO control followed by 
determination of luciferase activity.
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Figure 2. BMA097 inhibition of STAT3 activity and expression of STAT3 target genes
(A and B) Dose response and time course of BMA097 inhibition of STAT3-dependent 
luciferase expression. MDA-MB-231 cells with stable expression of STAT3-dependent 
luciferase were incubated with BMA097 at different concentrations (A) or at 2 μM for 
different times (B) followed by determination of luciferase activity. (C) BMA097 inhibition 
of STAT3 downstream target gene expression. MDA-MB-231 cells were treated without or 
with different concentrations of BMA097 followed by real-time RT-PCR analysis of 
mRNAs encoding STAT3, cyclin D1 and Bcl-xL. GAPDH was used as an internal control. 
(n=3; *p<0.05; **p<0.01).
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Figure 3. Effect of BMA097 on STAT3 phosphorylation and activation
(A–B) BMA097 inhibition of constitutive STAT3 phosphorylation. MDA-MB-231 cells 
were treated with different concentrations of BMA097 for 24 hrs (A and D) or at 2 μM for 
different times (B) followed by Western blot analysis of total and phosphorylated STAT3. 
STAT3 downstream target proteins Bcl-xL and Cyclin D1 were also tested. Actin was used 
as a loading control for Western blot. (C) BMA097 inhibition of IL-6-induced STAT3 
phosphorylation. Serum-starved MDA-MB-231 cells were pre-treated with BMA097 and 
then with IL-6 followed by Western blot analysis of total and Tyr705-phosphorylated STAT3. 
(D–E) BMA097 effect on pSTAT3 subcellular localization. MDA-MB-231 cells were treated 
without or with BMA097 for 24 hrs followed by immunofluorescence staining or 
fractionation and Western blot analysis of Tyr705-phosphorylated STAT3. DAPI was used to 
counterstain nuclei in panel D. Histone and actin were used as markers for nuclear and 
cytoplasmic fractions, respectively, in panel E. (F–G) Effect of BMA097 on STAT3 
dimerization. MDA-MB-231 cells were treated with BMA097 as described in panel A 
followed by separation using non-denaturing PAGE and Western blot analysis of STAT3. (H) 
Effect of BMA097 on JAK2 activation. MDA-MB-231 cells were treated with BMA097 
followed by Western blot analysis of total and Tyr1007/1008-phosphorylated JAK2.
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Figure 4. Binding of BMA097 to the SH2 domain of STAT3
(A–B) The predicted BMA097-binding pocket (A) and binding mode (B) in the SH2 domain 
of STAT3. Molecular surface in (A) is colored by dodger blue for the most hydrophilic to 
orange red for the most hydrophobic. The green lines in (B) indicate H-bonds. (C) Pull-
down assay. Total lysate from MDA-MB-231 cells were subjected to pull-down assay by 
CNBr-immobilized BMA097, an irrelevant compound (IC) or vehicle control followed by 
Western blot analysis of pull-down materials using STAT3 antibody. (D–E) Competition of 
STAT3-binding to immobilized BMA097 (D) or elution of STAT3 bound to the immobilized 
BMA097 (E) by excess free BMA097, DMSO vehicle control, or an irrelevant negative 
control compound (IC). (F) Schematic domain structures of STAT3 and of recombinant 
proteins. NTD, amino terminal domain; CCD, coiled coil domain; DBD, DNA-binding 
domain; LD, linker domain; SH2, Src homology 2 domain; TAD, transactivation domain. 
(G) Pull-down assay of purified recombinant STAT3 proteins with different deletions by 
immobilized BMA097.
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Figure 5. BMA097 inhibits proliferation and induces apoptosis in breast cancer cells
(A) Survival assay. Human breast cancer cells were treated with BMA097 at different 
concentrations for various times followed by MTT assay. (B–D) Apoptosis assay. Human 
breast cancer cells were treated with BMA097 at different concentrations (B and D) or at 2 
μM for different times (C) followed by Annexin V/PI (B–C) or JC-1 staining (D) and FACS 
analysis of apoptosis and mitochondrial membrane potential (Δψm). (*p <0.05; **p<0.01).
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Figure 6. BMA097 inhibits xenograft breast tumor growth and STAT3 phosphorylation and 
induces cancer cell apoptosis in vivo
(A) Volume of xenograft tumors and body weight of mice following treatments. (B–C) Wet 
weight and gross anatomy of final dissected xenograft tumor masses. (n= 5; *p <0.05; **p 
<0.01). (D) IHC staining of xenograft tumors using antibodies against total or Tyr705-
phosphorylated STAT3 and cleaved caspase 3.
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